Novartis to Acquire Anthos Therapeutics

Swiss drugmaker Novartis has agreed to acquire Anthos Therapeutics, a Boston, US-based biopharmaceutical company with its lead compound abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Under the terms of the agreement, Novartis will make an upfront payment of $925 million upon closing of the transaction and potential additional payments of up to $2.15 billion upon achievement of certain regulatory and sales milestones. The transaction is expected to close in the first half of 2025, subject to customary closing conditions.

Anthos Therapeutics, launched by Blackstone Life Sciences and Novartis in 2019, has advanced abelacimab through clinical development under a license from Novartis.

Abelacimab is a novel, highly selective, fully human monoclonal antibody that provides effective anticoagulation by inhibiting Factor XI, thereby minimizing blood clotting. Abelacimab is currently in Phase 3 development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation.

“We are excited to join forces to advance the development of abelacimab, a potential first-in-class treatment and safer approach for stroke prevention in atrial fibrillation as well as cancer-associated thrombosis,” said Shreeram Aradhye, president, Development and chief medical officer at Novartis.

In July 2022 abelacimab received a Fast Track Designation from the FDA for the treatment of thrombosis associated with cancer. In September 2022, the compound was also granted a Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

“Abelacimab is a potential first-in-class medicine, which promises to be an effective and safer approach to preventing thrombosis and stroke than the current standards of care,” said David Soergel, global head, Cardiovascular, Renal and Metabolism Development Unit at Novartis.

© Novartis
© Novartis

Company

Novartis International AG

Forum 1
4056 Basel
Switzerland

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.